(3.237.48.165) 您好!臺灣時間:2021/05/09 11:57
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:謝為忠
研究生(外文):Wei-Chung
論文名稱:XRCC1 T-77C基因多型性對手術後非小細胞肺癌預後之影響
論文名稱(外文):Prognostic significance of X-ray cross-complementing group 1 T-77C polymorphism in resected non-small cell lung cancer
指導教授:周明智周明智引用關係李輝李輝引用關係
指導教授(外文):Ming-Chih ChouHuei Lee
學位類別:博士
校院名稱:中山醫學大學
系所名稱:醫學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2011
畢業學年度:99
語文別:中文
論文頁數:124
相關次數:
  • 被引用被引用:0
  • 點閱點閱:168
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
研究目的:XRCC1是一種鹼基刪除DNA修補 (base excision repair) 基因。已知該基因有十七個基因多型性,其中位於促進子之T-77C基因多型性可調節基因的轉錄與人類肺癌症發生之相關性,在國外只有少數研究報告有提及。 XRCC1之T-77C基因型中具有TC或CC基因型者較TT者有較低轉錄活性,使其DNA修復蛋白複製量減少,故修復傷害的能力降低,因而增加罹患肺癌發生之風險。 在此本研究嘗試證明兩點, 首先XRCC1之T-77C基因多型性是否會增加台灣地區發生肺癌的風險(預測因子)?再則XRCC1之T-77C基因多型性是否與台灣非小細胞肺癌病患之存活率相關(預後因子)?
研究方法及材料:本研究共收集294位原發性肺癌病患之腫瘤周邊正常肺組織與288位非癌症者之血液DNA,以PCR-RFLP方式分析T-77C之基因多型性,並利用羅吉斯回歸分析不同基因型之XRCC1 T-77C與肺癌發生之相關性。本研究又以Kaplan-Meier方法統計分析不同基因型之XRCC1 T-77C與肺癌患者預後的相關性。
研究結果:結果發現XRCC1 T-77C基因多型性台灣地區肺癌發生之風險並無統計上之顯著差異。但進一步對非小細胞肺癌之存活分析,發現TT 基因型比 TC及CC基因型有較低的存活率(33.1% 比48.8% ; P= 0.031)。另Cox回歸分析亦顯示TT 基因型比 TC及CC基因型非小細胞肺癌病患死亡的機率增加1.84倍(95% CI, 1.16-2.86; P= 0.008)。
結論與建議:本研究的結論為XRCC1 T-77C基因變異型TC及CC可作為手術後非小細胞肺癌預後良好之獨立指標。

Objective:X-ray cross-complementing group 1 (XRCC1) is a base excision repair (BER) gene. There are 17 polymorphisms of XRCC1 been reported. Among these, the association of lung cancer risk and XRCC1 T-77C has been investigated by reduced transcriptional activity of XRCC1 which reduced the DNA repair capacity. A novel T-77C polymorphism in the promoter region of DNA repair gene X-ray cross-complementing group 1 (XRCC1) may modulate its transcription to increase the risk of lung cancer. However, we attempt to clarify: (1) whether the XRCC1 T-77C polymorphism was associated with lung cancer risk in Taiwanese and (2) whether the XRCC1 T-77C polymorphism could act as a prognostic indicator to predict the clinical outcome of non-small-cell lung cancer (NSCLC) patients.
Methods and Materials:294 primary lung cancer patients and 288 non-cancer potential controls were recruited into our study. Clinical data were collected. Adjacent normal lung tissues from lung cancer patients and venous bloods from non-cancer control subjects were enrolled for the collection of genomic DNA. Genotyping of the XRCC1 T-77C polymorphism was performed by polymerase chain reaction amplification. An unconditional multiple logistic regression was performed to obtain the odds ratio and 95% confidence interval for each variable between lung cancer cases and control group to understand the association of lung cancer risk. The association of XRCC1 genotypes with patient’s survival was statistically analyzed by Kaplan-Meier method and assessed using a log-rank test for each variable. Subsequently, a multiple Cox regression model was performed to obtain the adjusted hazard ratio and 95% confidence interval for potential prognostic factors in lung cancer patients.
Results:Our data showed that the XRCC1 T-77C polymorphism was not associated with the risk of lung cancer in Taiwanese patients. To verify the impact of the XRCC1 T-77C polymorphism on the clinical outcome of NSCLC, survival analysis showed the patients with TT genotype had a lower survival rate than those with the TC+CC genotypes (33.1% versus 48.8%, P= 0.031). The Cox regression analysis further indicated the patients with the TT genotype had a 1.84-fold risk compared with those with the TC + CC genotype (95%CI, 1.16-2.86; P= 0.008).
Conclusion and Suggestion:Our results suggest that XRCC1 T-77C variants (TC+CC) may act as a favorable prognostic indicator of resected NSCLC.

目 錄
壹、 文獻綜論 1
一、 肺癌之流行病學與臨床表現 1
1. 肺癌之流行病學研究 2
2. 肺癌之病理特徵、分期、治療與預後 2
2.1. 肺癌之病理特徵與分期 2
2.2. 非小細胞肺癌之治療與預後評估 4
2.3. 小細胞肺癌之治療與預後評估 9
3. 肺癌之危險因子 10
3.1. 香菸與肺癌形成之相關性 10
3.2. 香菸以外環境致癌物與肺癌形成之相關性 16
3.2.1. 二手菸、廚房油煙暴露與肺癌形成之相關性 18
3.2.2. 重金屬暴露與肺癌形成之相關性 21
3.2.3. 微生物感染與肺癌形成之相關性 22
3.3. 遺傳因素與肺癌形成之相關性 23
3.4. 性別差異與肺癌形成之相關性 24
二、 鹼基刪除修復(Base excision repair,BER) 26
三、 XRCC1(X-ray repair cross-complementing group 1) 28
1.基本分子結構與蛋白特性 28
2. XRCC1基因多型性與非小細胞肺癌發生之相關性 29
3. XRCC1基因多型性與非小細胞肺癌預後之相關性 32
貳、 研究動機 35
參、 研究設計與材料 38
一、 研究設計與檢體收集 38
二、 材料與藥品 40
1. 血液DNA萃取 40
2. 組織DNA萃取 40
3. 基因多型性及限制片段長度多形性(RFLP) 41
肆、 實驗方法 41
一、 肺癌病患非腫瘤組織樣本DNA萃取與純化 41
二、 健康者血液DNA萃取與純化 42
三、 聚合酶連鎖反應—限制片段長度多形性 43
1. XRCC1 T-77C 基因多型性分析 43
2. XRCC1 Arg194Trp 基因多型性分析 44
3. XRCC1 Arg399Gln 基因多型性分析 45
四、 DNA定序分析 46
1. PCR產物純化 46
2. DNA定序 47
五、 統計分析 48
伍、 結果 49
一、 肺癌病例組與健康對照組之年齡、性別、抽菸配對分佈 49
二、 XRCC1 T-77C基因多型性與非小細胞肺癌發生之
危險性評估 50
三、 XRCC1 T-77C基因多型性與非小細胞肺癌
預後影響之分析 52
陸、 討論 54
一、 遺傳與環境因素交互作用對肺癌發生之影響 54
二、 XRCC1 Arg194Trp及Arg399Gln基因多型性對
肺癌發生及預後之影響(本實驗室相關數據,未發表) 57
三、 XRCC1 T-77C基因多型性對非小細胞肺癌預後之影響
(本實驗室相關數據,未發表) 62
四、 未來之研究方向及展望 65
五、 結論 71
柒、 參考文獻 73
捌、 表與圖 89
玖、 附錄 125


柒、參考文獻

Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-26.

Ando Y, Ueoka H, Sugiyama T et al. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 2002; 24(1): 111-16.

Araki K, Fujita K, Ando Y et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006; 97: 1255-59.

Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 2004; 38:445-76.

Blackstock AW, Herndon JE, et al. Outcomes among African-American/non-African-American patients with advanced non-small cell lung cancer: report from the cancer and leukemia group B. J Natl Inst 2002; 94: 284.

Bosken CH, Wei Q, Amos Cl, Spitz MR. An analysis od DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002; 94: 1091-99.

Buccheri G, Ferrigno D, Tamburini M, et al. Karnofsky and ECOG performance status scoring in lung cancer: a prospective longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32: 1135.

Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001; 22: 593-97.

Cagini L, Monacelli M, Giustozzi G, et al. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J surg Oncol 2000; 74: 53.

Caldecott KW. XRCC1 and DNA strand break repair. DNA Repair (Amst) 2003; 2(9): 955-69.

Casse C, Hu YC, Ahrendt SA, et al. The XRCC1 codon 399 GLn allele is associated with adenine to guanine p53 mutaion in non-small cell lung cancer. Mutat Res 2003; 528: 19-27.

Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17: 1818-25.

Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet 2005; 162(1): 10-20.

Chen CC and Lee H. Genotoxicity and DNA adduct formation of incense smoke condensates: comparison with environmental tobacco smoke condensates. Mutat Res 1996 ; 367: 105-14.

Chen S, Tang D, Xue K, Xu L, Ma G, Hsu Y, Cho SS. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis 2002; 23(8):1321-5.

Cheng YW, Chen CY, Lin P, Chen CP, Huang KH, Lin TS, Wu MH, Lee H. DNA adduct level in lung tissue may act as a risk biomarker of lung cancer. Euro J Cancer 2000; 36: 1381-88.

Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, Chen CY, Su JM, Lee H. The Association of Human Papillomavirus 16/18 Infection with Lung Cancer among Nonsmoking Taiwanese Women. Cancer Res 2001; 61: 2799-2803.

Chiang TA, Wu PF, Ko YC. Identification of carcinogens in cooking oil fumes. Environ Res 1999; 81: 18-22.

Chiang TA, Wu PF, Wang LF, Lee H, Lee CH and Ko YC. Mutagenicity and polycyclic aromatic hydrocarbon content of fumes from heated cooking oils produced in Taiwan. Mutat Res 1997; 381: 157-61.

Chiou HL, Wu MF, Liaw YC, Cheng YW, Wong RH, Chen CY, Lee H. The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan. Cancer 2003; 15;97(6): 1558-63.

Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women: a post-hoc analysis of a randomized controlled trial. Lancet 2009; 143: 657

Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-23410666, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6: 3314

Clement-Duchene C, Vignaud JM, Stoufflet A, et al. Characteristics of never smoker lung xancer including environmental and occupational risk factors. Lung Cancer 2010; 67: 144.

De las Penas, M. Sanchez-Ronco, V. alberola et al. Polymorphism in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann of Oncol 2006; 17: 668-75.

De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, Claes K, Velghe A, Van Meerbeeck J, Thierens H. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res 2007;86:842-50.

De Wever, W, Ceyssens, S, Mortelmans, L, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone, and visual correlation of PET and CT. Eur Radiol 2007; 17: 23.

Divine KK, Gilliland FD, Crowell RE, Stidley CA, Bocklage TJ, Cook DL, Belinsky SA. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res 2001; 461: 273-278.

Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years’ observation on male brutish doctors. BMJ 2004; 328: 1519.

Fan J, Otterlei M, Wong HK, Tomkinson AE, Wilson DM 3rd. XRCC1 co-localizes and physically interacts with PCNA. Nucleic Acids Res 2004; 32(7): 2193-201.

Fan J, Wilson DM III. Protein-protein interactions and posttranslational modifications in mammalian base excision repair. Free Radic Biol Med 2005; 38(9): 1121-38.

Gao Y, Goldstein AM, Consonni D, et al. Family history of cancer and nonmalignant lung diseases as risk factors for lung cancer. Int J Cancer 2009;125:146.

Gao WM, Romkes M, Day RD, Siegfried JM, Luketich JD, Mady HH, Melhem MF, Keohavong P. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis 2003 24(10): 1671-6.

Gao WM, Romkes M, Siegfried JM, Luketich JD, Keohavong P. Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never-smokers. Mol Carcinog 2006; 45(11): 828-32.

Gao YT, Blot WJ, Zheng W, Ershow AG, Hsu CW, Levin LI, Zhang R, Fraumeni JF Jr. Lung cancer among Chinese women. Int J Cancer 1987; 15;40(5): 604-9.

Gazdar AF. DNA repair and survival in lung cancer – the two faces of Janus. N Engl J Med 2007; 356: 771-3.

Giovanni C, Daniele M, Corrado P, et al. Gastric cardia carcinoma is associated with the promoter -77T>C gene polymorphism of x-ray cross-complementing group 1. J Gastrointest Surg 2009; 13: 2233-38.

Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11(12): 1513-30.

Gorlova OY, Weng SF, Zhang Y, et al. Aggregation pf cancer among relatives of never-smoking lung cancer patients. Int J Cancer 2007; 121:111.

Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2007; 2: 694.

Gurubhagavatula S, Liu G, Park S et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22: 2594-2601.

Hao B, Miao X, Li Y, Zhang X, Sun T, Liang G, Zhao Y, Zhou Y, Wang H, Chen X, Zhang L, Tan W, Wei Q, Lin D, He F. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene 2006; 25: 3613-20.

Hao B, Wang H, Zhou K, Li Y, Chen X, Zhou G, Zhu Y, Miao X, Tan W, Wei Q, Lin D, He F. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 2004; 64(12): 4378-84.

Harald zur Hausen. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184(1): 9-13.

Harpole DH, Hernden JE, Young WG, et al. Stage I non-small cell lung cancer. A multivariate analysisof treatment mthods and patterns of recurrence. Cancer 1995; 76:787.

Havemann K, Hirsch FR, Ihde DC, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989; 5: 119.

Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stppoing randomized treatment with estrogen and progestion. JAMA 2008; 299:1036.

Hoang T, Xu R, Schiller JH, et al. Clinical mode to predict survival in chemonaive patients with advanced non-small cell lung cancer treated with third-generation chemotherapy regimen based on eastern cooperative oncology group data. J Clin Oncol 2005; 23: 175-183

Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancers. Nature 2001; 41: 366-74.

Hsieh LL, Chien HT, Chen IH, Liao CT, Wang HM, Jung SM, Wang PF, Chang JT, Chen MC, Cheng AJ. The XRCC1 399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 2003; 12(5): 439-43.

Hu Z, Ma H, Lu D, Zhou J, Chen Y, Xu L, Zhu J, Huo X, Qian J, Wei Q, Shen H. A promoter polymorphism (-77T>C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet Genomics 2005; 15(7): 457-63.

Huang CL, Yang CH, Yeh KH, et al. EGFR intron 1 dinucleotide repeat polymorphisms is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 2009; 64: 346-51.

Hung HS, Wu WJ, Cheng YW, Wu TC, Chang KL, Lee H. Association of cooking oil fumes exposure with lung cancer: Involvement of inhibitor of apoptosis proteins in cell survival and proliferation in vitro. Mutat Res 2007; 2;628(2): 107-16.

Hung RJ, Brennan P, Canzian F, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Chabrier A, Borel S, Hall J, Boffetta P. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst 2005; 97(8): 567-76.

Hung RJ, Bernan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidermiol 2005; 162: 925-42.

Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, Harris CC. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res 2001; 61(17): 6350-5.

Hussain SP, Hofseth LJ, Harris CC. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 2001; 34 Suppl 2:S7-15. Review.

Ito H, Matsuo K, Hamajima N, Mitsudomi T, Sugiura T, Saito T, Yasue T, Lee KM, Kang D, Yoo KY, Sato S, Ueda R, Tajima K. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis 2004; 25(8): 1395-401.

Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225.

Jemal A, Thun MJ, Ries LA, et al. Annular report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100: 1672.

Jiang J, Liang X, Huang R, et al. DNA repair gene X-ray repair cross complementing group 1 Arg194Trp polymorphism on the risk of lung cacner: a meta-analysis on 22 studies. J Thorac Oncol 2010; 5: 1741-7

Joachim S, Vera C, Simone Helmig. XRCC1 polymorphism and lung cancer risk. Expert Rev Mol Diag 2008; 8: 761.

Jordan P, Carmo-Fonseca M. Molecular mechanism involved in cisplatin toxicity. Cell Mol Life Sci 2000; 57: 1229-35.

Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisma predict favorable clinical outcome in advanced non-small cell lung cancer. Clinical Lung Cancer 2009; 10(2): 118-23.

Kang CH, Jang BG, Kim DW, et al. The prognostic significance of ERCC1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 2010; 68: 478-83.

Karnofsky D, Abelmann W, Vraver L, et al. The use of nitrogen mustard in the palliative treatment of cancer. Cancer 1948; 1:634.

Kartalou M, essigmann JM. Mechanisms of resistance to cisplatin. Mutation Res 2001; 478: 23-43.

Kabat GC, Miller AB, Rohan TE, et al. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer 2007; 120: 2214.

Kato R. Sex-related difference in drug metabolism. Drug Metab Rev 1994; 3(1): 1-32.

Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26957 patients with NSCLC. J Thorac Oncol 2010; 5:620.

Kayo OSAWA. Gene polymorphisms and chemotherapy in non-small-cell lung cancer. Chin J Lung Cancer 2009; 12: 837-40.

Kiyohara C TK, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 2006; 54: 267-83.

Kuo CY, Wong RH, Lin JY, Lai JC, Lee H. Accumulation of chromium and nickel metals in lung tumors from lung cancer patients in Taiwan. J Toxicol Environ Health A 2006; 69(14): 1337-44.

Kurahashi N, Inoue M, Liu Y, et al. Passive smoking and lung cancer in Japanese non-smoking women: a prospective study. Int J Cancer 2008; 122: 653.

Kvale PA, Simoff M, Prakash UB, et al. Lung cancer. Palliative care. Chest 2003; 123: 284S.

Lai JC, Cheng YW, Chiou HL, Wu MF, Chen CY, Lee H. Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non-small cell lung cancer. Int J Cancer 2005 117(6): 974-80.

Lee CH, Ko YC, Goggins W, Huang JJ, Huang MS, Kao EL, Wang HZ. Lifetime environmental exposure to tobacco smoke and primary lung cancer of non-smoking Taiwanese women. Int J Epidemiol 2000; 29(2): 224-31.

Lee JM, Lee YC, Yang SY, Yang PW, Luh SP, Lee CJ, Chen CJ, Wu MT. Genetic polymorphisms of XRCC1 and risk of the esophageal cancer. Int J Cancer 2001; 95(4): 240-6.

Leelakumari S, Volga SS, Vani S, et al. Prognostic importance of DNA repair gene polymorphisms od XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol 2008; 134: 645-52.

Lee W, Jiang Z, Liu J et al., The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465: 473-77

Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88(3): 323-31.

Li D, Li Y, Jiao L, Chang DZ, Beinart G, Wolff RA, Evans DB, Hassan MM, Abbruzzese JL. Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer 2007; 120(8): 1748-54.

Lodovici M, Akpan V, Caldini S, Akanju B, Dolara P. DNA solution(R) in cigarette filters reduces polycyclic aromatic hydrocarbon (PAH) levels in mainstream tobacco smoke. Food Chem Toxicol 2007;78: 876-82.

Long JR, Cai Q, Shu XO, Cai H, Gao YT, Zheng W. Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival. Pharmacogenet Genomics 2007; 17(5): 331-8.

Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999; 59(11): 2557-61.

Lupulescu A. Hormonal regulation of epidermal tumor development. J Invest Dermatol 1981; 77(2): 186-95.

Martini N, Bain MS, Burt ME, et al. Incidence of local recurrenceand secondary primary tumors in resected stage I lung cancer. J Thorac cardiovasc surg 1995; 109:120.

Misra RR, Ratnasinghe D, Tangrea JA, Virtamo J, Andersen MR, Barrett M, Taylor PR, Albanes D. (2003) Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett, 191(2): 171-8.

Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010; 277: 301-8.

Mitsudomi T. Advance in target therapy for lung cancer. Jpn J Clin Oncol 2010; 40: 101-6.

Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor recptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98: 1817-24.

Mollerup S, Jorgensen K, Berge G, et al. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer: 37: 153.

Mosselman S, Polman J, Dijkema R. ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49.

Nomura M, Shigematsu H, Li L. et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small-cell lung cancers. PLoS Med 2007; 4: e125

Olassen KA, Dunant a, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-91.

Olshan AF, Watson MA, Weissler MC, Bell DA. XRCC1 polymorphisms and head and neck cancer. Cancer Lett 2002; 178: 181-186.

Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer; update of a systematic review and meta-analysis by the European Lung Cancer Staging Project. J Thorac Oncol 2010; 5: 612.

Park JY, Lee SY, Jeon HS, Bae NC, Chae SC, Joo S, Kim CH, Park JH, Kam S, Kim IS, Jung TH. (2002) Polymorphism of the DNA Repair Gene XRCC1 and Risk of Primary Lung Cancer. Cancer Epidemiol Biomarkers Prev, 11(1): 23-7.

Park SY, Lam W, Cheng YC. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 2002; 62(2): 459-65.

Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA cancer J Clin 2005; 55: 74.

Patel JD, Gray RG, Stewart JA, et al. Tamoxifen does not reduce the risk of lung cancer on women. J of Clin Oncol 2005; 23:673.

Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891-903.

Qu T, Morii E, Oboki K, Lu Y, Morimoto K. Micronuclei in EM9 cells expressing polymorphic forms of human XRCC1. Cancer Lett 2005; 221(1): 91-5.

Ray G, Husain SA. Oxidants, antioxidants and carcinogenesis. Indian J Exp Biol 2002; 40: 1213– 32.

Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006; 355: 1054-55.

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of ertrogen plus progestin in healthy postmenopausal women: principal results from the women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321.

Rubin H. Synergistic mechanisms in carcinogenesis by polycyclic aromatic hydrocarbons and by tobacco smoke: a bio-historical perspective with updates. Carcinogenesis 2001; 22(12): 1903-30.

Ryk C, Kumar R, Sanyal S, de Verdier PJ, Hemminki K, Larsson P, Steineck G, Hou SM. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett 2006; 241(1): 142-9.

Ryk C, Kumar R, Thirumaran RK, Hou SM. Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. Lung Cancer 2006; 54(3): 285-92.

Sang MY, Hong YC, Heon JP, et al. The polymorphism and haplotypes of XRCC1 and survival of non-small cell lung cancer after radiotherapy. Int J Rad Oncol Biol Phys 2005; 63: 885-91.

Schiller JH, Harrington D, Belani CP et al; Comparison of four chemotherapy regimen for advanced non-small cell lung cancer, N Engl J Med 2002; 346: 92-98 .

Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non-small-cell lung cancer in women. J Clin Oncol 2007; 25: 5785.

Sculier JP, Chansky K, Crowley JJ, et al. The impact of additional prognostic factorson survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant tumors and the proposals for the 7th Edition. J Thorac 2008; 3: 457.

Seikido YFK, Minna JD. Cancer of the lung. In: DeVita VT, Hellman S, Roseberg SA, editors. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott-Raven 2001; 917-83.

Seo SK. Infectious complications of lung cancer. Oncology (Williston Park) 2005; 19(2): 185-94; discussion 195-6, 199-203, 207-8. Review.

Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical feature and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247.

Shellard SA, Fichtinger-Schepman AM, Lazo JS, et al. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 1993; 4: 491-500.

Shen H, Xu Y, Qian Y, Yu R, Qin Y, Zhou L, Wang X, Spitz MR, Wei Q. Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population. Int J Cancer 2000; 88(4): 601-6.

Silvestri GA, Tanoue LT, Margolis ML, et al. The noninvasive staging of non-small-cell lung cancer: the guidelines. Chest 2003; 123: 147S

Slatore CG, Chien JW, Au DH, et al. Lung cancer and hormone replacement therapy: Association in the Vitamins and Lifestyle Study. J Clin Oncol 2010; 28: 1540.

Sorahan T, Burges DC, Hamilton L, Harrington JM. Lung cancer mortality in nickel/chromium platers, 1946–95 Occup. Environ. Med 1998 ; 55, pp. 236 - 242.

Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Mol Carcinog 2006; 45(9): 715-9.

Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 125-131.

Strano S, Dell''Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene 2007; 26(15): 2212-9.

Sturgis EM, Castillo EJ, Li L, Zheng R, Eicher SA, Clayman GL, Strom SS, Spitz MR, Wei Q. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 1999; 20: 2125-2129.

Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent non-small cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007; 83: 409.

Sugimura T, Nagao M, Wakabayashi K. Carcinogenicity of food mutagens. Environ Health Perspect 1996; 104 Suppl 3:429-33.

Sun X, Li F, Sun N, et al. Polymorphisms in XRCC1 and XPG and respone to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009; 65(2): 230-6.

Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL, Vaughan TL. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003;12(6): 527-33.

Taioli E, Wynder EL. Endocrine factors and adenorcarcinoma of lung cancer in women. J Natl Cancer Inst 1994; 86: 869.

Tanvetyanon T, Robinson LA, schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008; 26: 1142.

Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010; 17: 889.

Tiseo M, Capelletti M, de Palma G et al. Epidermal growth factor receptor intron -1 polymorphism predicts gefinitib outcome in advanced non-small-cell lung cancer. J Thorac Oncol 2008; 3: 1104-11.

Thompson LH, West MG. XRCC1 keeps DNA from getting stranded. Mutat Res 2000; 459(1): 1-18.

Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and genetics: Tumors of the Lung, Pleura, Thymus and Heart. Lyon IARC, 2004.

Van de Vaart PJ, Blederbos J, de Jong D et al. DNA-adducts levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000; 89: 160-66.

Vineis P, Hoek G, Krzyzanowski M, et al. Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study. Environ Health 2007; 6: 7.

Wang Y, Yang H, Li H, et al. Association between X-ray repair cross complementing group 1 codon 399 and 194 polymorphisms and lung cancer risk: a meta-analysis. Cancer Lett 2009; 285: 134-40.

Wang YC, Chen CY, Chen SK, Cherng SH, Ho WL, Lee H. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Cancer Res 1998; 58(2): 328-33.

Wei Q, Cheng L, Amos Cl et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidermiologic study, J Natl Cancer Inst 2000: 92: 1764-72.

Wood RD, Mitchell M, Sgouros J, et al. Human DNA repair genes. Science 2001, 291:1284-9.

Wood RD, Lindadl T. Human DNA repair genes. Mutat Res 2005, 577:275-83.

Wu CT, Chan YL, Shih JY, et al. The significance of estrogen receptors beta in 301 surgically treated non-small-cell lung cancers. J thorac Cardiovasc Surg 2005; 130: 979.

Wynder EL., Muscat JE. The changing epidemiology of smoking and lung cancer histology. Environ Health Perspect 1995; 103 Suppl 8:143-8.

Xi L, Coello MC, Litle VR, et al. A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer res 2006; 12: 2484.

Yang CC, Jenq SN, Lee H. Characterization of the carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in cooking aerosols under domestic conditions. Carcinogenesis 1998; 19(2): 359-6.

Yao CY, Huang XE, Li C, et al. Lack of influenceof XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non-small cell lung cancers. Asian Pac J Cancer Prev 2009; 10: 859-64.

Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer 2007; 56(2): 153-60.

Yin Z, Zhou B, He Q, et al. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer 2009; 15: 439.

Yuan P, Liu L, Wu C, et al. No association between XRCC1 polymorphis and survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Biol Ther 2010; 3: 10(9)

Zeng-Rong N, Paterson J, Alpert L, et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 1995; 55: 4760-4.

Zhang X, Miao X, Liang G, Hao B, Wang Y, Tan W, Li Y, Guo Y, He F, Wei Q, Lin D. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res, 2005; 65(3): 722-6.

Zhonghua Wang, Binghe Xu, Dongxin Lin, et al. XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer 2008; 62: 99-104.

Zhou W, Liu G, Miller DP, Thurston SW, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. Polymorphisms in the DNA Repair Genes XRCC1 and ERCC2, Smoking, and Lung Cancer Risk. Cancer Epidemiol Biomarkers Prev 2003; 12(4): 359-65.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, Phillips DH, Canzian F, Haugen A. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006; 27(3): 560-7.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關論文
 
1. 基因表觀遺傳機制調控麩胱甘肽轉移酶在肺癌細胞及早期非小細胞肺癌患者中的表現之研究
2. Slit2的exon15剪接變異型對抑制肺癌細胞生長及侵犯能力的影響
3. 建構非小型細胞肺癌基因體整合型資料庫:IGDB.NSLCL
4. 肺腺癌中新抗凋亡因子的表現與臨床預後
5. 磁振造影技術於診斷及藥物遞送之應用:以氧化鐵奈米粒子應用於非小細胞肺癌為例
6. 表皮生長因子受體蛋白經由活化Cdk5/p35進而調控非小型細胞肺癌之細胞生長與移動
7. 探討PITX2B基因表現在非小細胞肺癌之角色
8. 非小細胞肺癌的臨床治療預後與Id 蛋白質的相關性--- Id 蛋白質可作為肺癌病人接受化學治療的預測因子
9. Aldo-keto reductase 1C2 的過度表現與攝護腺癌的進展有關
10. 多酚天然物 resveratrol 和 quercetin 增強 cisplatin 毒殺肺癌細胞之能力
11. 找尋可預測與監測非小細胞肺癌標靶治療成效的腫瘤生物標誌
12. 台灣眼翳致病機轉之研究:(I)甲基轉移酵素3b與p16INK4a轉錄起始區過度甲基化的關聯性(II)去氧核醣核酸修補基因 APE1、hOGG1及XRCC1 之基因多型性之分析
13. 區域醫療資源及論質計酬對不同社經位置糖尿病患健康照護品質與健康結果的影響-多層次分析
14. 順、逆式肉桂酸生理功效之探討 (I) 對人類肺癌細胞侵入轉移性之抑制功效 (II) 對多重抗藥性結核菌生長抑制與藥物協同功效
15. 探討TNFAIP3與BCL2基因調節在不同癌症之特異性
 
系統版面圖檔 系統版面圖檔